Gold prices bounce off 3-week lows; demand likely longer term
NEW YORK - Goldman Sachs & Co (NYSE:GS). LLC disclosed on Monday its trading activities involving shares of Mural Oncology PLC, a company listed on the stock exchange. According to a statement released on May 19, 2025, the investment bank engaged in multiple transactions involving Mural Oncology’s USD 0.01 ordinary shares on May 16, 2025.
The dealings are part of the disclosure requirements under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2013, which mandates that any person with interests in relevant securities representing 1% or more must report their transactions.
Goldman Sachs reported both long and short positions in Mural Oncology. The long positions after the dealings amounted to 180,360 securities, representing approximately 1.04% of the company’s relevant securities. The short positions totaled 183,665 securities, or roughly 1.06% of the relevant securities.
The transactions included a series of purchases at prices ranging from $2.5500 to $2.6500 per share. Notably, the largest single purchase was for 15,640 shares at a price of $2.6500 each. Sales were also reported at a price of $2.6500 per share, including one sale of 16,100 shares.
In addition to the trades in ordinary shares, Goldman Sachs disclosed a derivative transaction in the form of a purchased swap related to one relevant security with an exercise price of $0.0000, set to expire on July 8, 2025.
The disclosure did not indicate any agreements, arrangements, or understandings relating to options or derivatives between Goldman Sachs and any other parties.
This trading activity comes amid the standard disclosure practices within the financial industry, where investment banks and other financial entities are required to publicly report their dealings in securities that meet certain criteria. The information is based on a press release statement and is intended to maintain transparency in financial markets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.